Check up: What’s happening with ASX small cap health stocks
Here’s our fortnightly wrap of all the news driving ASX small cap health stocks.
We last checked in with ASX small cap health stocks just hours after Opthea’s (ASX:OPT) anti macular degeneration drug passed a large clinical test with flying colours.
The share price responded accordingly and has continued its upward trajectory in the last fortnight.
Opthea’s CEO believes the best is yet to come from the company as it undertakes further tests and seeks to commercialise. It is up over 300 per cent in 12 months and has held firm despite a hefty full year loss.
But Opthea is not the biggest gainer in 12 months. This is held by medical imaging provider Resonance Health (ASX:RHT), which gained another 28 per cent this fortnight. Yet no news has come out of the company since its last quarterly.
Nanollose (ASX:NC6) is down over the 12-month period but it was the second biggest gainer this fortnight. The catalyst was a co-operation with global wipes maker Codi. The pair will work together to develop their own products.
A stock that fascinated us at Stockhead was Race Oncology (ASX:RAC). It is currently in a clinical trial for a drug targeting a cancer that’s too small a market opportunity for big pharma.
An investment by a prominent biotech entrepreneur led to the stock surging on Monday.
Failed clinical trials can send companies plunging – just ask Factor Therapeutics (ASX:FTT) which is still down over 90 per cent.
But another bad news story is when your founder is departing and that’s what happened to Adalta (ASX:1AD).
Samantha Cobb announced last week she would be leaving the company she had founded and grown into the firm it is today. Adalta is down 34 per cent.
Medibio (ASX:MEB) surged late last month after contract wins, but in the last fortnight it has launched a capital raise.
On an industry wide basis, stocks were unchanged in the last fortnight but have gained 11 per cent in the last 12 months. In the last fortnight there were 68 stocks that gained, 45 that fell and 22 which were stagnant.
Here are all 135 ASX small cap health and biotech stocks and their performance in the past fortnight:
Swipe or scroll to reveal the full table. Click headings to sort